Financial groups and labor unions urge FTC to block Nordisk Foundation's acquisition of Catalent, citing concerns about ...

CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.

The site also serves as an oral solids development and small-scale manufacturing facility for the pharmaceutical company, ...

Ardena inks agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey: Ghent, Belgium Tuesday, October 15, 2024, 16:00 Hrs [IST] Ardena, a specialist pha ...

Catalent entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer ...

Novo Holdings is set to buy one less facility from Catalent as the manufacturer has sold a facility in New Jersey to a ...

Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to ...

The FDA-approved Somerset facility employs approximately 200 skilled scientists and technicians and is a Center of Excellence for advanced delivery of oral dosage forms, complementing Ardena's ...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...

Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said. ** Private equity ...